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INTRODUCTION
Lipoprotein(a) (Lp(a)) is a unique lipoprotein particle, which consists of an apolipoprotein B containing lipoprotein moiety very similar to low-density lipoprotein (LDL) covalently linked to the glycoprotein component apoprotein(a) [apo(a)]
1 . Apo(a) is exclusively produced in the liver, and its secretions highly correlated with circulating Lp(a) levels 2 . Clinical and epidemiological evidence reveals an increased level of Lp(a) to be a causal, independent risk factor for cardiovascular disease (CVD) [3] [4] [5] [6] . The atherogenic properties of Lp(a) are associated with several mechanisms, including the inhibition of the fibrinolitic system by homologous structure of apo(a) with plasminogen 7 , the interaction with extracellular matrix conjugates such as glycoproteins 8 , the binding to scavenger receptors on macrophages 9, 10 , and the induction of inflammatory molecules 11 .
Given the above, there has been an interest in Lp(a) as a target for residual risk therapy [12] [13] [14] .
In general, circulating Lp(a) levels are genetically determined 15 , while the levels can change in certain circumstances, such as under acute vascular and inflammatory pathologies [16] [17] [18] . The
European Atherosclerosis Society (EAS) Consensus Panel recommends screening for elevated
Lp(a) in those at intermediate or high CVD/coronary heart disease (CHD) risk, a desirable level <50 mg/dL as a function of global CV risk, and use of niacin for Lp(a) and CVD/CHD risk reduction 19 . Since currently available LDL cholesterol-lowering drugs, such as statins, have little effects of Lp(a), and other, such as niacin is poorly tolerated and is not available in many countries, there has been a continuous search for effective agents for lowering circulating Lp(a) levels 20 .
Tibolone (Livial, Org OD 14) is a synthetic steroid with estrogenic, androgenic and progestogenic properties, and used orally for the prevention of osteoporotic bone loss and M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT
4 hormonal replacement treatment on climacteric symptoms in postmenopausal women 21, 22 .
Tibolone itself has no activities, but two estrogenic metabolites (3α-and 3β-hydroxy [OH] tibolone) and the third metabolite (∆4-tibolone) exert the effects on climacteric symptoms, and the third metabolite also exerts additional progestogenic effects in endometrium 23, 24 . Tibolone treatment can modulate the lipid profile and its possible reduction of Lp(a) has been observed 25 ,
although the effects of tibolone on Lp(a) were not previously analysed within systematic review and meta-analysis 22 . Therefore, we performed a meta-analysis to evaluate the efficacy of tibolone treatment on circulating Lp(a) levels in postmenopausal women.
MATERIAL AND METHODS
Search Strategy
This study was designed according to the guidelines of the 2009 preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement 26 . PubMed 
Study Selection
Original studies (all in postmenopausal women) were included if they met the following inclusion criteria: (i) being a controlled clinical study (RCT, controlled perspective or open-label study), (ii) investigating the impact of tibolone on plasma/serum concentrations of Lp(a), (iii) presentation of sufficient information on Lp(a) concentrations at baseline and at the end of follow-up in each group or providing the net change values.
Exclusion criteria were: (i) lack of a an appropriate control group in the study design, (ii)
non-clinical observational studies with case-control, cross-sectional or cohort design, (iii) lack of sufficient information on baseline or follow-up Lp(a) concentrations, (iv) inability to obtain adequate details of study methodology or results from the article or the investigators, and, (v) the study was ongoing.
Data extraction
Eligible studies were reviewed and the following data were abstracted: 1) first author's name; 2) year of publication; 3) study location; 4) study design; 5) tibolone dose and the route of administration; 6) number of participants in the tibolone and control groups; 7) inclusion and exclusion criteria; 8) age, gender and body mass index (BMI) of study participants; 9) prevalence of diabetes mellitus; and 10) baseline and follow-up plasma concentrations of Lp(a).
Quality assessment
A systematic assessment of bias in the included studies was performed using the Cochrane criteria 27 . The items used for the assessment of each study were as follows: adequacy of sequence generation, allocation concealment, blinding, addressing of dropouts (incomplete outcome data), selective outcome reporting, and other potential sources of bias. According to the recommendations of the Cochrane Handbook, a judgment of "yes" indicated low risk of bias, while "no" indicated high risk of bias. Labeling an item as "unclear" indicated an unclear or unknown risk of bias.
Quantitative Data Synthesis
Meta-analysis was conducted using Comprehensive Meta-Analysis (CMA) V2 software (Biostat, NJ) 28 . Net changes in measurements (change scores) were calculated as follows:
measure at end of follow-up − measure at baseline. For cross-over trials, net change in plasma concentrations of Lp(a) were calculated by subtracting the value after control intervention from that reported after treatment. All values were collated in percentage changes from baseline levels. Standard deviations (SDs) of the mean difference were calculated using the following formula: SD = square root [(SD pre-treatment ) 2 + (SD post-treatment ) 2 -(2R × SD pre-treatment × SD posttreatment )], assuming a correlation coefficient (R) = 0.5. If the outcome measures were reported in median and inter-quartile range, mean and standard SD values were estimated using the method described by Hozo et al. 29 . Where standard error of the mean (SEM) was only reported, standard deviation (SD) was estimated using the following formula: SD = SEM × square root (n), where n is the number of subjects. When the results were presented in multiple time points, only data relating to the longest duration of treatment were considered.
A random-effects model (using DerSimonian-Laird method) and the generic inverse variance method were used to compensate for the heterogeneity of studies in terms of demographic characteristics of populations being studied and also differences in study design.
Heterogeneity was quantitatively assessed using I 2 index. Effect sizes were expressed as weighted mean difference (WMD) and 95% confidence interval (CI). In order to evaluate the influence of each study on the overall effect size, sensitivity analysis was conducted using leaveone-out method, i.e. removing one study each time and repeating the analysis 30, 31 .
Meta-regression
Random-effects meta-regression was performed using unrestricted maximum likelihood method to evaluate the association between calculated WMD and potential moderators including duration of treatment with tibolone.
Publication bias
Potential publication bias was explored using visual inspection of Begg's funnel plot asymmetry, fail-safe N test, and Begg's rank correlation and Egger's weighted regression tests.
Duval & Tweedie "trim and fill" method was used to adjust the analysis for the effects of publication bias 32 .
RESULTS
The search provided 82 articles excluding duplicates. Of those, 67 were excluded after initial screening and the remaining 15 full text papers were reviewed. Finally 12 were scrutinized as full texts and were selected to be included in the analysis [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] . The reasons for excluding the M A N U S C R I P T
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8 remaining 3 articles were: not controlled for tibolone (n=2) and no tibolone treatment arm (n=1) (Figure 1 ). In total, 1009 participants were randomized, of whom 634 were allocated to tibolone supplementation group and 375 to control group in the selected studies. The number of participants in these studies ranged from 6 to 136. They were published between 1996 and 2009, and were conducted in USA, Greece, Ireland, the Netherlands (3 trials), Italy (2 trials), UK, Serbia and Turkey. A range of tibolone doses from 0.3 to 2.5 mg/day was administered in the included trials. Duration of supplementation with tibolone ranged between 3 and 60 months.
Tibolone was safe and well-tolerated in all included studies with no report of any drug-related adverse events. Baseline parameters of the included studies are shown in Table 1 .
Risk of bias assessment
According to the Cochrane Collaboration 45 , a specific tool for assessing risk of bias in each involved study comprises judgment of specific features of the study. This involves evaluating the risk of bias as 'low risk', 'high risk or 'unclear risk'. The last category shows either lack of information or uncertainty over the potential for bias. There are seven analyzed domains comprising: sequence generation (selection bias), allocation sequence concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective outcome reporting (reporting bias) and other potential sources of bias ( Table 2) .
Effect of tibolone on plasma Lp(a) concentrations
Overall, the impact of tibolone on plasma Lp(a) concentrations were reported in 12 trials 
Publication bias
The funnel plot of the study standard error by effect size (WMD) was symmetric, suggesting lack of publication bias in the analysis of the effect tibolone on plasma Lp(a) concentrations. 
DISCUSSION
The present meta-analysis of data from 12 trials comprising 16 treatment arms revealed that oral tibolone treatment significantly reduced circulating Lp(a) levels in postmenopausal women.
These results are of high importance because Lp(a) is an independent risk factor for CVD, there are no effective and safe treatments for high Lp(a) levels, and postmenopausal women are at higher CVD risk [3] [4] [5] .
Tibolone treatment can reduce circulating Lp The influences of the dose and duration of used drugs on Lp(a) is also of concern 25 . Niacin can reduce Lp(a) in a dose-dependent manner 53 . Whereas, the present meta-analysis did not find a dose-or duration-dependent manner of tibolone treatment on Lp(a). This may be an advantage in using tibolone to decrease Lp(a) levels.
The reduction of circulating Lp(a) by tibolone is still incompletely explained. The estrogenic property of tibolone is a possible explanation of the reduction of Lp(a) 25 ; however, the details in However, further studies of the mechanism of action of tibolone on Lp(a) metabolism are still required.
The present meta-analysis has limitations. First, the studies included in the present metaanalysis were not always interventional studies focused on the Lp(a) levels, as a main endpoint, therefore well-designed interventional trials specific for Lp(a) are still necessary. Next, the included studies did not evaluate the long-term CVD outcomes associated with Lp(a) reduction.
The reduction of Lp(a) is theoretically thought to be favorable for the prevention of the events, but whether the reduction of Lp(a) with Lp(a)-targeted therapies can lead to the favorable outcomes still needs to be proven, especially that available long-term controlled studies with a Lp(a)-lowering drug (nicotinic acid plus laropiprant) have failed to find a positive impact of the Lp(a) reduction on CV events 19 . Some studies have also indicated that very low Lp(a) levels might be harmful 57, 58 , however Mendelian randomization studies did not confirm that low Lp(a) increases the risk of diabetes 59 . However, tibolone can improve not only Lp(a) level but also vascular functions (e.g. vasodilation) with its estrogenic property 21 . Additionally, tibolone is reported to modulate other lipoprotein factors, i.e. the drug with its androgenic properties can reduce high-density lipoprotein cholesterol (HDL-C) as an unfavorable change 25 . However, there are findings that the change of HDL-C is usually transient 33 ; on the other hand there are more and more data that we should not focus on HDL-C as it is not main target of the lipidlowering therapy, also due to the lasting debate on HDL functionality in different patients'
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groups 42, 60, 61 . It should be emphasized that data on circulating Lp(a) levels were obtained from studies using different assays for Lp(a). It would be also necessary to look at the tibolone effects in general, including the influence on inflammatory markers, and other risk factors of CVD (e.g.
blood pressure) 62 , in order to finally confirm the possible benefits of its therapy. Finally, the included studies did not particularly focus on tibolone therapy-related side effects. One should notice that the side effects after tibolone therapy with doses ≤2.5 mg/day are uncommon 63 . In increased of the stroke risk. There were also no significant differences in the risk of either CHD or venous thromboembolism 64 . However the above mentioned stroke risk was not observed in other studies with younger postmenopausal women 65, 66 .
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